Suven Life Sciences Management

Management criteria checks 2/4

Suven Life Sciences' CEO is Venkat Jasti, appointed in Oct 2004, has a tenure of 19.58 years. directly owns 0.001% of the company’s shares, worth ₹202.23K. The average tenure of the management team and the board of directors is 13.7 years and 10 years respectively.

Key information

Venkat Jasti

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	19.6yrs
CEO ownership	0.0009%
Management average tenure	13.7yrs
Board average tenure	10yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Venkat Jasti's remuneration changed compared to Suven Life Sciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-₹1b
Dec 31 2023	n/a	n/a	-₹1b
Sep 30 2023	n/a	n/a	-₹1b
Jun 30 2023	n/a	n/a	-₹1b
Mar 31 2023	n/a	n/a	-₹1b
Dec 31 2022	n/a	n/a	-₹1b
Sep 30 2022	n/a	n/a	-₹940m
Jun 30 2022	n/a	n/a	-₹991m
Mar 31 2022	n/a	n/a	-₹1b
Dec 31 2021	n/a	n/a	-₹1b
Sep 30 2021	n/a	n/a	-₹1b
Jun 30 2021	n/a	n/a	-₹1b
Mar 31 2021	n/a	n/a	-₹722m
Dec 31 2020	n/a	n/a	-₹761m
Sep 30 2020	n/a	n/a	-₹745m
Jun 30 2020	n/a	n/a	-₹787m
Mar 31 2020	n/a	n/a	-₹942m
Dec 31 2019	n/a	n/a	₹28m
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹871m
Mar 31 2019	₹58m	₹29m	-₹239m
Mar 31 2018	₹47m	₹25m	₹1b

Compensation vs Market: Insufficient data to establish whether Venkat's total compensation is reasonable compared to companies of similar size in the Indian market.

Compensation vs Earnings: Venkat's compensation has increased whilst the company is unprofitable.

CEO

Venkat Jasti (74 yo)

19.6yrs

Tenure

Mr. Venkateswarlu Jasti, also known as Venkat, M.Pharm. M.S., is Member of Advisory Council of Suven Pharmaceuticals Limited since 2024. Mr. Jasti served as Executive Director at Suven Pharmaceuticals Limi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Venkateswarlu Jasti	Executive Chairman & CEO	19.6yrs	no data	0.00092% ₹ 202.2k
Sudharani Jasti	Whole-Time Director	35.2yrs	₹9.99m	0.00092% ₹ 202.2k
M. Kumar	Chief Financial Officer	4.3yrs	no data	no data
Shrenik Soni	Company Secretary & Compliance Officer	4.3yrs	no data	no data
Kalyani Jasti	President of US Operations	13.7yrs	no data	0.00092% ₹ 202.2k

13.7yrs

Average Tenure

69yo

Average Age

Experienced Management: 530239's management team is seasoned and experienced (13.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Venkateswarlu Jasti	Executive Chairman & CEO	35.2yrs	no data	0.00092% ₹ 202.2k
Sudharani Jasti	Whole-Time Director	35.2yrs	₹9.99m	0.00092% ₹ 202.2k
Seyed Hasnain	Non-Independent & Non-Executive Director	14.1yrs	₹230.00k	no data
Santanu Mukherjee	Independent Non-Executive Director	6yrs	₹330.00k	no data
Jasthi Ananthasai Padmaja	Independent Non-Executive Director	5.5yrs	₹170.00k	no data
Vajja Rao	Director	less than a year	no data	no data

10.0yrs

Average Tenure

69yo

Average Age

Experienced Board: 530239's board of directors are seasoned and experienced ( 10 years average tenure).

Suven Life Sciences Management

Management criteria checks 2/4

Key information

Recent management updates

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Insufficient new directors

Suven Life Sciences Limited, Annual General Meeting, Aug 04, 2022

Recent updates

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.92 loss per share (vs ₹2.90 loss in 3Q 2023)

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Life Sciences Limited to Report Q3, 2024 Results on Jan 30, 2024

New major risk - Share price stability

Suven Life Sciences Limited to Report Q4, 2024 Results on May 15, 2024

Second quarter 2024 earnings released: ₹0.58 loss per share (vs ₹1.59 loss in 2Q 2023)

New minor risk - Share price stability

Suven Life Sciences Limited to Report Q2, 2024 Results on Nov 04, 2023

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.05 loss in FY 2022)

Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.57 loss in FY 2022)

Third quarter 2023 earnings released: ₹2.90 loss per share (vs ₹2.65 loss in 3Q 2022)

Suven Life Sciences Limited to Report Q3, 2023 Results on Feb 02, 2023

Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

Price target decreased to ₹306

Insufficient new directors

Second quarter 2023 earnings released

Suven Life Sciences Limited to Report Q2, 2023 Results on Nov 08, 2022

Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022

Suven Life Sciences Limited to Report Q1, 2023 Results on Jul 26, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited Declares One-Time Special Dividend for the Financial Year 2021-22, Payable on and from 25 May, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited, Annual General Meeting, Aug 04, 2022

Suven Life Sciences Limited to Report Q4, 2022 Results on May 07, 2022

Price target decreased to ₹306

Insufficient new directors

Suven Life Sciences Limited Declares Interim Dividend, Payable on and from 22 February 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: ₹2.22 loss per share (vs ₹1.23 loss in 2Q 2021)

Price target decreased to ₹306

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Price target increased to ₹472

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Suven Life Sciences Limited announced that it has received INR 369.10425 million in funding from Jasti Family Trust

Independent Non-Executive Director has left the company

Third quarter 2021 earnings released: ₹1.92 loss per share (vs ₹1.79 loss in 3Q 2020)

Suven Life Sciences Limited to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: ₹57.90

First half earnings released

New 90-day high: ₹56.45

Insider recently bought ₹1.0m worth of stock

New 90-day high - ₹54.50

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 17, 2020

First quarter earnings released

New 90-day high - ₹48.55

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 11, 2020

Price target raised to ₹537

Suven Life Sciences Limited(BSE:530239) dropped from S&P Global BMI Index

CEO Compensation Analysis

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age